Table 2.
Results of the Markov cohort model for patients with microsatellite stable endometrial cancer.
N = 5000 each cohort | Pembrolizumab/Lenvatinib | Carboplatin/Paclitaxel |
---|---|---|
Respond (n) | 1106 | 1626 |
Progress (n) | 742 | 622 |
Death (n) | 3151 | 2752 |
Cost ($) | 261,518 | 48,848 |
Difference in costs | 212,670 | |
Effectiveness (QALY) | 1.40 | 1.68 |
Difference in QALYs | −0.28 |